Trial document

This study has been imported from without additional data checks.
drksid header


Trial Description

start of 1:1-Block title


Open Prospective Within Patient, Phase IIa Study of Hexvix Flexible Cystoscopy and White Light Cystoscopy in the Detection of Bladder Cancer After 30 Minutes Instillation of Hexvix in Patients With Known or Suspicion of Bladder Cancer

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym


end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial


end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

The objective of the study is to compare Hexvix® flexible cystoscopy and white light
flexible cystoscopy in the detection of histological confirmed bladder tumor lesions defined
as dysplasia; CIS; Ta; T1; and ≥ T2 after 30 minutes intravesical instillation of Hexvix®.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

This study is an open, prospective, within patient, controlled, multi-center, Phase IIa
study in patients with bladder cancer.

The bladder of all patients will be instilled with 50 mL Hexvix® 8 mM solution and evacuated
after 30 minutes. After bladder evacuation, the bladder will be examined under white light
cystoscopy using the Karl Storz flexible videocystoscope. Tumors visible under white light
will be mapped. Then the bladder is evaluated with blue light and lesions seen by blue light
will be mapped. Biopsies of all visible tumors will be taken using both white and blue light
prior to resection of all lesions.

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00004099
  •   2012/10/09
  •   2012/03/02
  •   no
  •   [---]*
  •   [---]*
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   NCT01551407  (
  •   PC B202/11  (PhotoCure)
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   Bladder Cancer
  •   C67 -  Malignant neoplasm of bladder
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Drug: Hexvix
end of 1:N-Block interventions
start of 1:1-Block design


  •   Interventional
  •   [---]*
  •   Single arm study
  •   Open (masking not used)
  •   [---]*
  •   Uncontrolled/Single arm
  •   Diagnostic
  •   Single (group)
  •   II
  •   [---]*
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

- Number of lesions; time frame: An average of 15 min (during cystoscopy)

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

- Drug related adverse events; time frame: From time of drug instillation until 24 hours after cystoscopy

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

end of 1:n-Block recruitment locations
start of 1:1-Block recruitment


  •   [---]*
  •   2011/12/31
  •   34
  •   [---]*
  •   [---]*
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

The patients should be indicated for a transurethral resection of the bladder (TURB) based
on an outpatient cystoscopy and fulfil the following inclusion criteria:

- Patients with multiple bladder tumors, defined as ≥2 lesions, based on an outpatient

- Patients with known urinary urge symptoms or patients who have problems or pain
holding back the urine for a time longer than 30 minutes.

- Age 18 years or above

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

- Patients with known tumors in the prostatic urethra or distal urethra

- Gross haematuria. (Note: Gross haematuria is defined as a heavy bladder bleed
resulting in marked amounts of blood in the urine, which may interfere with
fluorescence cystoscopy. Where the bleed is light, the patient should not be excluded
if in the investigator's opinion, rinsing during cystoscopy will alleviate the
possible interference with fluorescence cystoscopy).

- Patient with porphyria.

- Hypersensitivity to the active substance or to any of the excipients of the solvent

- Participation in other clinical studies with investigational drugs either
concurrently or within the last 30 days.

- Women of child-bearing potential meaning that only post-menopausal women, women who
had their ovaries removed, and women who are otherwise physically unable to bear
children can be included.

- Patients who have received BCG or chemotherapy within three months prior to study

- Conditions associated with a risk of poor protocol compliance.

- Patient is the investigator or any sub investigator, research assistant, pharmacist,
study coordinator, other staff or relative thereof directly involved in the conduct
of the protocol

- Mental condition rendering the subject unable to understand the nature, scope, and
possible consequences of the clinical study.

- Patients unlikely to comply with protocol

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses


  • start of 1:1-Block address primary-sponsor
    • Photocure
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Department of Urology, LMU Munich, Germany
    • Alexander Karl, MD 
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Department of Urology, LMU Munich, Germany
    • Alexander Karl, MD 
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state


  •   Recruiting stopped after recruiting started
  •   2012/06/01
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
The parameters in and DRKS are not identical. Therefore the data import from required adjustments. For full details please see the DRKS FAQs .
  •   7
  •   2016/01/14

* This entry means the parameter is not applicable or has not been set.